Nextcure Inc (NXTC)

$13.22 -0.51 (-3.71%)
Market Cap 48.13M
Revenue (ttm) 0.00
Net Income (ttm) -55.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 88,600
Avg Vol 32,752
Day's Range N/A - N/A
Shares Out 3.51M
Stochastic %K 56%
Beta 1.54
Analysts Strong Sell
Price Target $17.67

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 399 4900
Address:
9000 Virginia Manor Road, Suite 200, Beltsville, United States
emeraldstocktrader
emeraldstocktrader Feb. 22 at 11:42 PM
$NXTC has a promising candidate in this space CDH6... and MSD acquired assets including a CDH6 for 22B ... bullish!
0 · Reply
emeraldstocktrader
emeraldstocktrader Feb. 19 at 7:11 PM
$NXTC buy alert! This drug is worth 50x based on comps!!
1 · Reply
neilyoungsband
neilyoungsband Feb. 3 at 2:37 PM
$NXTC buying at .10 cents burn this pos to the ground.
0 · Reply
emeraldstocktrader
emeraldstocktrader Feb. 2 at 4:15 PM
$NXTC buying here 🚨
0 · Reply
PickAlpha
PickAlpha Jan. 24 at 2:49 PM
3/4: NextCure reports ~$41.8M year-end cash, guides funding runway into 1H 2027 | View: Extended runway into 1H 2027 eases near-term dilution risk… $NXTC $XBI
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 11:51 PM
$NXTC Current Stock Price: $13.34
0 · Reply
emeraldstocktrader
emeraldstocktrader Jan. 14 at 6:11 PM
$NXTC 🚨 love it
1 · Reply
emeraldstocktrader
emeraldstocktrader Dec. 31 at 6:11 PM
$NXTC buying here 🚨
2 · Reply
kshonstocks
kshonstocks Dec. 30 at 4:50 PM
$NXTC 97 name on scans https://research.investors.com/stock-quotes/nasdaq-nextcure-nxtc.htm
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 3:59 AM
$NXTC
0 · Reply
Latest News on NXTC
NextCure Provides Business Update

Jan 23, 2026, 7:00 AM EST - 4 weeks ago

NextCure Provides Business Update

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 3 months ago

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Nov 17, 2025, 8:00 AM EST - 3 months ago

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Nov 12, 2025, 8:00 AM EST - 3 months ago

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 3 months ago

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Oct 16, 2025, 8:05 AM EDT - 4 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 6 months ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 7 months ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jul 24, 2025, 4:05 PM EDT - 7 months ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 10:03 AM EDT - 9 months ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Jun 16, 2025, 7:05 AM EDT - 9 months ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025, 4:05 PM EDT - 9 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 10 months ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 11 months ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Jan 10, 2025, 8:05 AM EST - 1 year ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Sep 16, 2024, 8:05 AM EDT - 1 year ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 4:10 PM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 30, 2024, 4:05 PM EDT - 1 year ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 4:05 PM EDT - 1 year ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 8, 2024, 7:00 AM EDT - 2 years ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 4, 2024, 7:05 AM EDT - 2 years ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 2 years ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:55 AM EDT - 2 years ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Mar 5, 2024, 8:05 AM EST - 2 years ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Jan 18, 2024, 4:05 PM EST - 2 years ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

NextCure Provides Year-End Clinical Pipeline Updates

Dec 14, 2023, 6:45 AM EST - 2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Oct 17, 2023, 8:05 AM EDT - 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 12, 2023, 8:05 AM EDT - 2 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 7, 2023, 4:05 PM EDT - 2 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Jun 21, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

NextCure to Present at the JMP Securities Life Sciences Conference

May 9, 2023, 7:00 AM EDT - 3 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

May 4, 2023, 4:05 PM EDT - 3 years ago

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

Apr 11, 2023, 7:00 AM EDT - 3 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 3 years ago

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

emeraldstocktrader
emeraldstocktrader Feb. 22 at 11:42 PM
$NXTC has a promising candidate in this space CDH6... and MSD acquired assets including a CDH6 for 22B ... bullish!
0 · Reply
emeraldstocktrader
emeraldstocktrader Feb. 19 at 7:11 PM
$NXTC buy alert! This drug is worth 50x based on comps!!
1 · Reply
neilyoungsband
neilyoungsband Feb. 3 at 2:37 PM
$NXTC buying at .10 cents burn this pos to the ground.
0 · Reply
emeraldstocktrader
emeraldstocktrader Feb. 2 at 4:15 PM
$NXTC buying here 🚨
0 · Reply
PickAlpha
PickAlpha Jan. 24 at 2:49 PM
3/4: NextCure reports ~$41.8M year-end cash, guides funding runway into 1H 2027 | View: Extended runway into 1H 2027 eases near-term dilution risk… $NXTC $XBI
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 11:51 PM
$NXTC Current Stock Price: $13.34
0 · Reply
emeraldstocktrader
emeraldstocktrader Jan. 14 at 6:11 PM
$NXTC 🚨 love it
1 · Reply
emeraldstocktrader
emeraldstocktrader Dec. 31 at 6:11 PM
$NXTC buying here 🚨
2 · Reply
kshonstocks
kshonstocks Dec. 30 at 4:50 PM
$NXTC 97 name on scans https://research.investors.com/stock-quotes/nasdaq-nextcure-nxtc.htm
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 3:59 AM
$NXTC
0 · Reply
DunnDunn86
DunnDunn86 Dec. 29 at 7:49 PM
$NXTC What happened suddenly, jumped 5% ... gl ✨
1 · Reply
GlacierGuard
GlacierGuard Dec. 26 at 5:08 PM
$NXTC Price action signals that reliability now matters more than headline momentum. Margin trajectory needs to confirm that scale creates leverage, not dilution. Overextension would degrade optionality during downturns. Sentiment should follow consistency rather than noise.
0 · Reply
HieronymusBosch
HieronymusBosch Dec. 12 at 3:27 PM
$NXTC loving this
0 · Reply